● Recruiting

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

Condition: Platinum-resistant Ovarian Cancer · Sponsor: Roswell Park Cancer Institute

PhasePhase 1

Planned participants18

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This phase 1 study evaluates the safety, efficacy, and biological activity of GB-5267 in patients with platinum-resistant ovarian cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Ask RPCI · 716-845-2300 · askroswell@roswellpark.org

Always discuss trial participation with your own doctor first.

Locations (1)

Roswell Park Comprehensive Cancer Center

Buffalo, New York, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07489287